Pharminent · Daily Brief

November 19, 2026
Regulatory & Approvals

FDA approves Infilbray for Type 3 Gaucher disease symptoms

The FDA approved Infilbray (venglustat) tablets, the first treatment for the neurological symptoms of Type 3 Gaucher disease, in adults and pediatric patients weighing at least 15 kg (approximately 33 pounds).

FDA →

FDA approves Regeneron’s Livsayis for generalized myasthenia gravis

The FDA approved Regeneron’s Livsayis (cemdisiran) for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive.

Pharmaceutical Technology →$REGN

FDA publishes rejection letter for Summit’s ivonescimab

The FDA published its complete response letter for Summit Therapeutics’ ivonescimab, detailing several issues the agency had with the application. Sellas shares rose on results for its leukemia vaccine, and Biogen and Lilly struck new R&D pacts.

BioPharma Dive →$BIIB$LLY

White House withdraws FDA nomination of Heidi Overton

The White House withdrew its nomination of Dr. Heidi Overton to lead the FDA.

PharmExec →

FDA case against alternative funding program hinged on CEO informant

The FDA’s criminal case against CanaRx, an alternative funding program, relied on the cooperation of a peer CEO, according to a court record.

CNBC →
Clinical Data

Mixed data for experimental Alzheimer’s therapies presented at CTAD

The CTAD Alzheimer’s meeting featured encouraging data for drug candidates from Biogen, AriBio and BMS, alongside disappointing results from other programs.

Pharmaphorum →$BIIB$BMY
Deals & Partnerships

Pfizer signs $2.6B in vivo CAR-T deal with Starna

Pfizer entered a potentially $2.6 billion collaboration with Starna Therapeutics for global rights, excluding Greater China, to three preclinical in vivo CAR-T cell therapy programs for autoimmune conditions.

BioPharma Dive →$PFE

Merck and Isomorphic Labs partner on oncology small molecules

Merck and Isomorphic Labs said they are entering a research collaboration to discover small molecule drug candidates in oncology.

STAT →$MRK

Vertex and Genomics extend discovery alliance in $220M deal

Vertex Pharmaceuticals and Genomics agreed to a four-year extension of their drug discovery partnership, in a deal with a potential value exceeding $220 million.

Pharmaceutical Technology →$VRTX
Business & Finance

Novartis raises peak sales forecasts for blockbuster drugs to $18B

Novartis upgraded peak sales forecasts for its multiple sclerosis, leukemia and cholesterol medicines to $18 billion, citing strong demand for the drugs.

CNBC →$NVS

Hone Health raises $228M for longevity platform

Hone Health secured $228 million, consisting of $28 million in Series A equity financing and $200 million in growth financing from General Catalyst’s Customer Value Fund.

MedCity News →

Hims & Hers launches compounded peptide treatments

Hims & Hers will offer compounded forms of sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, none of which are approved by the FDA, while acknowledging more remains to be learned about their efficacy.

CNBC →

Get the signal in your inbox

Sign up free →

Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.